FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | GlaxoSmithKline | India | Novartis | drug safety

ALSO NOTED: Ex-Chinese drug official gets 15 years;Sun gets FDA nod for generic dementia drug;

Tools

> A former Chinese drug regulator has been sentenced to 15 years in prison for bribery and embezzlement; the harsh punishment is seen as an example of the country's crackdown on food and drug safety. Report

> India's Sun Pharma got the FDA's blessing for its generic version of Exelon, an Alzheimer's and Parkinson's remedy made by Novartis--but won't launch the drug immediately because of outstanding patent litigation. Report

> GlaxoSmithKline has sold 2 million starter kits of its Alli weight-loss product in the five months since it was introduced; the results were in line with company expectations. Report

> A group of researchers are focused on developing a new, nonhormonal contraceptive that uses RNAi technology to silence the ZP3 gene, which is required to fertilize an egg during ovulation. Report

> A molecular mechanism at work during periods of stress may shed light on developing new therapies for post-traumatic stress disorder and other conditions. Report

And Finally... Americans love their sleeping pills, paying $4.5 billion for them annually. But patients think they work better than they really do. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about India   Novartis   drug safety   FDA   GlaxoSmithKline